Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Oral and anal carriage of Neisseria meningitidis among sexually active HIV-infected men who have sex with men in Denmark 2014-15

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Silent Hypoxia in Patients with SARS CoV-2 Infection before Hospital Discharge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sex differences in congestive markers in patients hospitalized for acute heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Hydroxychloroquine has been proposed as a primary prophylactic agent against COVID-19. We aimed to investigate if patients treated with hydroxychloroquine for a non-SARS-CoV-2-indication had a lower risk of verified infection with SARS-CoV-2, compared with matched controls.

METHODS: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e. both during and before SARS-CoV-2 was confirmed in Denmark) matched by age and sex with controls. Data were collected using the Danish national registries containing complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection.

RESULTS: A total of 5,488 hydroxychloroquine-users were matched with 54,486 non-users. At baseline the groups differed on diagnoses of pulmonary, cardiovascular, renal,gastrointestinal / metabolic disease and dementia as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indication was not associated with any change in confirmed SARS-CoV-2 [HR of 0.90 (95% Confidence Interval 0.76-1.07)] This result was robust in the propensity-score matched sensitivity analysis.

CONCLUSION: Our study, which is the largest to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.

OriginalsprogEngelsk
TidsskriftInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN1201-9712
DOI
StatusE-pub ahead of print - 1 jun. 2021

ID: 66135180